<DOC>
	<DOCNO>NCT01323530</DOCNO>
	<brief_summary>This Phase 1b/2 , multi-center , open-label , dose escalation dose-and-schedule confirmation study eribulin administer combination capecitabine .</brief_summary>
	<brief_title>A Phase 1b/2 , Multicenter , Randomized , Open-Label , Dose-Escalation Confirmation Study Eribulin Combination With Capecitabine</brief_title>
	<detailed_description />
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Inclusion Criteria Subjects meet follow criterion include study : Doseescalation cohort ( Phase 1b ) : 1 . Histologically cytologically confirm cancer advance and/or metastatic 2 . Resistant/refractory approve therapy ( define progressive disease within 6 month last anticancer therapy ) single agent capecitabine dose level schedule would reasonable treatment option opinion investigator 3 . For subject previously receive capecitabine , capecitabine related toxicity must completely resolve 4 . Adequate bone marrow function evidence absolute neutrophil count ( ANC ) great equal 1.5 x 10^9/L , hemoglobin great equal 10.0 g/dL ( may correct growth factor transfusion ) , platelet count great equal 100 x 10^9/L 5 . Adequate liver function evidence bilirubin less equal 1.5 time upper limit normal ( ULN ) alkaline phosphatase ( AP ) , alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) less equal 3 x ULN ( case liver metastases less equal 5 x ULN ) . In case AP great 3 x ULN ( absence liver metastasis ) great 5 x ULN ( presence liver metastasis ) AND subject also know bone metastasis , liver specific AP must separate total use ass liver function instead total AP . 6 . Adequate renal function evidence calculated creatinine clearance great equal 50 mL/min per CockcroftGault formula ( Appendix 1 ) radioisotope measurement . 7 . Females childbearing potential must negative urine serum beta hCG Visit 1 ( Screening ) prior start study drug Day 1 . Female subject childbearing potential must agree abstinent use highly effective method contraception ( e.g. , condom + spermicide , condom + diaphragm spermicide , intrauterine device ( IUD ) , vasectomized partner ) start least one menstrual cycle prior start study drug ( ) throughout entire study period 30 day ( longer appropriate ) last dose study drug . Those woman use hormonal contraceptive must also use additional approve method contraception ( describe previously ) . Perimenopausal woman must amenorrheic least 12 month consider nonchildbearing potential . 8 . Male subject abstinent undergone successful vasectomy , partner woman childbearing potential must use , partner must use , highly affective method contraception ( e.g . condom + spermicide , condom + diaphragm spermicide , IUD ) start least one menstrual cycle prior start study drug ( ) throughout entire study period 30 day ( longer appropriate ) last dose study drug . Those partner use hormonal contraceptive must also use additional approve method contraception ( describe previously ) 9 . Life expectancy great 3 month 10 . Willing able comply aspect protocol 11 . Provide write informed consent 12 . Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) less equal 2 13 . Males female , age great equal to18 year Doseconfirmation cohort ( Phase 2 ) : 1 . Histologically cytologically confirm carcinoma breast advance and/or metastatic 2 . Received three prior chemotherapy regimen set ( sequential neoadjuvant/ adjuvant treatment count one regimen ) 3 . Chemotherapy regimens must include anthracycline ( unless anthracycline contain chemotherapy inappropriate ) taxane , either combination separate regimens 4 . No prior treatment capecitabine set 5 . At least one lesion great equal 1.5cm long diameter nonlymph node great equal 1.5cm short diameter lymph node serially measurable accord Response Evaluation Criteria Solid Tumors ( RECIST ) version 1.1 7 6 . Adequate bone marrow function evidence absolute neutrophil count ( ANC ) great equal 1.5 x 10^9/L , hemoglobin great equal 10.0 g/dL ( may correct growth factor transfusion ) , platelet count great equal 100 x 10^9/L 7 . Adequate liver function evidence bilirubin less equal 1.5 time upper limit normal ( ULN ) alkaline phosphatase ( AP ) , alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) less equal 3 x ULN ( case liver metastases less equal 5 x ULN ) . In case AP great 3 x ULN ( absence liver metastasis ) great 5 x ULN ( presence liver metastasis ) AND subject also know bone metastasis , liver specific AP must separate total use ass liver function instead total AP . 8 . Adequate renal function evidence calculated creatinine clearance great equal 50 mL/min per CockcroftGault formula ( Appendix 1 ) radioisotope measurement . 9 . Females childbearing potential must negative urine serum beta hCG Visit 1 ( Screening ) prior start study drug Day 1 . Female subject childbearing potential must agree abstinent use highly effective method contraception ( e.g. , condom + spermicide , condom + diaphragm spermicide , IUD , vasectomize partner ) start least one menstrual cycle prior start study drug ( ) throughout entire study period 30 day ( longer appropriate ) last dose study drug . Those woman use hormonal contraceptive must also use additional approve method contraception ( describe previously ) . Perimenopausal woman must amenorrheic least 12 month consider nonchildbearing potential 10 . Life expectancy great 3 month 11 . Willing able comply aspect protocol 12 . ECOGPS 0 1 13 . Females , age great equal 18 year Exclusion Criteria Subjects meet follow criterion exclude participation study : 1 . Radiotherapy , chemotherapy , biological therapy investigational agent within 4 week prior start study treatment ; subject must recover previous therapy relate toxicity less Grade 1 study entry ( except stable sensory neuropathy less equal Grade 2 alopecia ) 2 . Treatment mitomycin C nitrosourea within 6 week prior commence study treatment 3 . Hormonal treatment within 2 week prior start study treatment ( continue use antiandrogens and/or gonadorelin analogue treatment prostate cancer permit ) 4 . Prior participation eribulin clinical study , even assign eribulin treatment 5 . Subject hypersensitivity halochondrin B /or halochondrin B chemical derivates capecitabine excipients 6 . Suspected dihydropyrimidine dehydrogenase ( DPD ) deficiency 7 . Previous radiotherapy encompass great 30 % marrow 8 . Previous organ allograft require immunosuppression 9 . Subjects brain subdural metastasis eligible , unless complete local therapy discontinue use corticosteroid indication least 4 week start study treatment . Any symptom attribute brain metastasis must stable least 4 week start study treatment ; radiographic stability determine compare contrastenhanced compute tomography ( CT ) magnetic resonance imaging ( MRI ) brain scan perform screen prior scan perform least 4 week earlier 10 . Meningeal carcinomatosis 11 . Significant cardiovascular impairment ( history congestive heart failure great NYHA grade II , unstable angina myocardial infarction within past 6 month , serious cardiac arrhythmia ) 12 . Electrocardiogram ( ECG ) QTc interval great 470 msec ( measure either Bazett 's Fredericia 's formula ) 13 . Preexisting neuropathy great Grade 2 14 . Anticoagulant therapy warfarin related compound , line patency , change heparinbased therapy duration study 15 . Subjects know positive serology Human Immunodeficiency Virus ( HIV ) , Hepatitis B C 16 . Subjects significant disease disorder , Investigator 's opinion , would exclude subject study 17 . Major surgery within 4 week start study treatment schedule surgery project course study 18 . Unable swallow tablet</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>metastatic breast cancer</keyword>
</DOC>